Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NVS NYSEARCA:XLV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVSNovartis$122.80-0.5%$121.88$96.06▼$130.46$260.59B0.631.07 million shs754,949 shsXLVHealth Care Select Sector SPDR Fund$136.94+0.2%$135.30$127.35▼$155.01$33.95B0.711.51 million shs9.90 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVSNovartis-0.51%-0.07%-3.26%+4.13%+5.53%XLVHealth Care Select Sector SPDR Fund+0.23%+0.01%-0.89%+2.27%-11.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVSNovartis$122.80-0.5%$121.88$96.06▼$130.46$260.59B0.631.07 million shs754,949 shsXLVHealth Care Select Sector SPDR Fund$136.94+0.2%$135.30$127.35▼$155.01$33.95B0.711.51 million shs9.90 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVSNovartis-0.51%-0.07%-3.26%+4.13%+5.53%XLVHealth Care Select Sector SPDR Fund+0.23%+0.01%-0.89%+2.27%-11.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNVSNovartis 2.00Hold$120.33-2.01% DownsideXLVHealth Care Select Sector SPDR Fund 2.68Moderate Buy$136.94N/ACurrent Analyst Ratings BreakdownLatest NVS and XLV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025NVSNovartisThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Sell$119.00 ➝ $118.008/21/2025NVSNovartisDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/8/2025NVSNovartisMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$123.00(Data available from 9/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNVSNovartis$50.32B5.16$10.65 per share11.53$21.59 per share5.69XLVHealth Care Select Sector SPDR FundN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNVSNovartis$11.94B$6.8717.8813.941.7325.64%41.08%16.83%10/28/2025 (Estimated)XLVHealth Care Select Sector SPDR FundN/AN/A21.15∞N/AN/AN/AN/AN/ALatest NVS and XLV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/17/2025Q2 2025NVSNovartis$2.38$2.42+$0.04$2.06$13.94 billion$14.05 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNVSNovartis$2.602.12%N/A37.85%N/AXLVHealth Care Select Sector SPDR Fund$2.391.75%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNVSNovartis0.530.820.62XLVHealth Care Select Sector SPDR FundN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNVSNovartis13.12%XLVHealth Care Select Sector SPDR FundN/AInsider OwnershipCompanyInsider OwnershipNVSNovartis0.01%XLVHealth Care Select Sector SPDR FundN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNVSNovartis75,8832.11 billion2.11 billionOptionableXLVHealth Care Select Sector SPDR FundN/A247.91 millionN/ANot OptionableNVS and XLV HeadlinesRecent News About These CompaniesRevvity Stock: Is RVTY Underperforming the Healthcare Sector?September 23 at 4:12 PM | msn.comBoost Your Portfolio With These Top-Ranked ETFsSeptember 19, 2025 | zacks.comSenator Jack Reed has filed a new financial disclosure - here’s what we seeSeptember 18, 2025 | quiverquant.comQHow Is ResMed's Stock Performance Compared to Other Healthcare Stocks?September 15, 2025 | msn.comXLV: Market Overreaction Could Drive Double Digit Shareholder YieldSeptember 12, 2025 | seekingalpha.comDownbeat August Jobs Data Puts Focus on These Sector ETFsSeptember 8, 2025 | zacks.comHealthcare Valuations Near Multi-Year Lows Suggest Risk–Reward AsymmetrySeptember 2, 2025 | investing.comIs Healthcare Setting Up to Be a Quiet Leader Into Year-End?...September 2, 2025 | marketbeat.comXLV Vs. IHE: Will Pharmaceuticals Outperform Healthcare?August 28, 2025 | seekingalpha.comHealthcare stocks: are they well-positioned to weather Trump tariffs?August 25, 2025 | invezz.comITop 5 ETFs and Stocks to Watch as the Fed Eyes Rate Cuts (XLV)...August 25, 2025 | marketbeat.comHealthcare ETF Discount Highlights Value Ahead of Ozempic Growth CycleAugust 21, 2025 | msn.comIs This the Right Time to Consider Healthcare ETFs?August 21, 2025 | zacks.comOzempic Boom: Hims & Eli Lilly Lead Healthcare Bets (XLV)...August 21, 2025 | marketbeat.comShould You Invest in the Health Care Select Sector SPDR ETF (XLV)?August 14, 2025 | zacks.comTHW: Discounted Valuation Due To Higher Interest RatesAugust 8, 2025 | seekingalpha.comHealthcare: Winning Sector ETF Amid Soft U.S. July Jobs ReportAugust 6, 2025 | zacks.comEarnings Scorecard: 18 out of 21 healthcare firms beat earnings forecast this weekAugust 3, 2025 | msn.comBeyond Broad Healthcare: A Smarter Prescription for GrowthAugust 1, 2025 | etftrends.comE12 out of 12 healthcare firms top revenue estimates this week: Earnings ScorecardJuly 27, 2025 | msn.comXLV: Life Expectancy, Patents, And A Positive Outlook Will Pave The WayJuly 16, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Take Profits Now: 3 Overbought Stocks Primed for a PullbackBy Dan Schmidt | August 25, 2025Is Healthcare Setting Up to Be a Quiet Leader Into Year-End?By Ryan Hasson | September 2, 2025Novartis' Moonshot Cancer Therapy Could Be Future Growth DriverBy Chris Markoch | September 9, 2025NVS and XLV Company DescriptionsNovartis NYSE:NVS$122.80 -0.56 (-0.45%) Closing price 09/23/2025 03:59 PM EasternExtended Trading$122.82 +0.02 (+0.01%) As of 09/23/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Health Care Select Sector SPDR Fund NYSEARCA:XLV$136.94 +0.31 (+0.23%) Closing price 09/23/2025 04:10 PM EasternExtended Trading$137.02 +0.08 (+0.06%) As of 09/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Mega-Cap Giants Just Increased Dividends by 7% or More 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Amprius Technologies: Anatomy of a Textbook, Raging Bull Market Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
